Scope, Claims, and U.S. Patent Landscape for Drug Patent US 11,844,804
US 11,844,804 claims a clinical titration method for testosterone that starts with subcutaneous (SC) dosing and selects the lowest SC dose that achieves a target blood plasma testosterone concentration, while benchmarking against an intramuscular (IM) dose that achieves the same target. The core hook is the “lowest SC dose” selection framed against equivalent plasma attainment using SC versus IM, coupled to additional limitations around SC concentration, weekly dosing, stability criteria across weeks, and maintained therapeutic ranges.
What does the independent claim cover?
Claim 1 (independent) recites a method of titrating a patient to a lowest dose of testosterone while achieving a desired blood plasma concentration.
Claim 1 elements (scope-defining)
- Goal: Obtain a desired blood plasma concentration of testosterone in plasma.
- Route: Subcutaneously administer doses of testosterone.
- Titration approach: Use 2 or more SC doses and select the lowest dose that provides the desired plasma concentration.
- Comparative benchmark: The “desired plasma concentration” is compared to (and anchored against) an intramuscular dose that provides the same desired plasma concentration.
- Deliverable outcome: The method ends with the patient titrated to the lowest SC dose that matches the plasma concentration achieved by IM dosing at that target.
Practical claim interpretation
- The claim is not directed to the testosterone drug product itself. It is directed to the clinical method and dosing decision-making process.
- The claim demands that the target plasma concentration is treated as equivalent across routes by reference to an IM dosing regimen that reaches that same target.
- The “lowest dose” is defined in relation to the same patient population being titrated with SC doses, using the plasma concentration as the yardstick.
What must be proven for infringement (method claims)
A challenger must show (a) SC titration with at least two doses, (b) plasma measurement used to identify a “desired” target range (or point), (c) selection of the lowest SC dose achieving that target, and (d) that the desired target is the same as a target that an IM dose would produce (as stated in the claim).
How do the dependent claims narrow scope?
Claims 2-11 progressively narrow the dose, formulation concentration, dosing interval, week-to-week stability, continuation after reaching target, dose-change flexibility post-achievement, and explicit testosterone concentration ranges.
How do claims 2–4 set dose magnitude?
Claim 2: The lowest dose is 50 mg to 100 mg but states specifically:
- “from between 50 mg, 75 mg and 100 mg” (i.e., a low-dose band with discrete endpoints implied by the listed values).
Claim 4: Repeats and broadens slightly:
- “between 50 mg and 100 mg” for the lowest dose.
Scope effect: These claims lock the “lowest SC dose” into a relatively narrow mg band. They can still cover different exact lowest-dose outcomes inside the range, but they exclude SC lowest doses outside 50-100 mg for those dependent claim embodiments.
How do claims 3 set SC formulation concentration?
Claim 3: The SC administered dose concentration is 100 mg/ml, 150 mg/ml, or 200 mg/ml.
Scope effect: This makes the formulation concentration a limiting feature for that dependent claim. It narrows method embodiments to specific product strengths (if those strengths are used during titration).
How do claims 5–6 define dosing schedule and stability?
Claim 5: Prescribed time period for SC administration is weekly.
Claim 6: After the desired plasma concentration is reached, an average plasma concentration after a subsequent dose or doses must satisfy a stability criterion:
- The average obtained after administration of a subsequent dose or doses is less than ±30% of the average plasma concentration obtained during the immediately preceding week.
Scope effect: Claim 6 turns the method into an ongoing maintenance titration/stability test:
- It is not enough to hit target once. The method requires that week-to-week averages remain within a tolerance band (±30%) relative to the immediately preceding week.
How do claims 7–8 handle dosing after reaching target?
Claim 7: SC doses are continued after reaching desired plasma concentration.
Claim 8: Post-achievement SC doses can be:
- the same or different SC doses compared to pre-achievement doses.
Scope effect: Claim 8 eliminates an argument that the lowest dose must remain fixed forever. It explicitly allows adjustment after reaching target, without taking you outside the claim set.
How do claims 9–11 define the target testosterone plasma range?
The independent claim 1 covers “desired blood plasma concentration” broadly. Dependent claims specify target ranges.
- Claim 9: about 800 ng/dl to 1100 ng/dl
- Claim 10: about 500 ng/dl to 800 ng/dl
- Claim 11: about 350 ng/dl to 500 ng/dl
Scope effect: These ranges offer discrete candidate therapeutic target bands. They also signal that the invention is designed around clinically typical testosterone “on-treatment” targets and maintenance levels.
Claim set architecture (what combinations matter)
Below is the effective “stacking” of limitations when dependent claims are read in order:
| Claim |
Route |
Dose selection framework |
Lowest dose band |
Weekly dosing |
SC concentration (mg/ml) |
Stability after reach |
Target range limitation |
| 1 |
SC |
Select lowest of 2+ SC doses hitting desired plasma conc anchored to IM equivalence |
50-100 mg not required in C1 |
Not required |
Not required |
Not required |
Desired plasma conc required but not range-fixed |
| 2 |
SC |
Same as C1 |
50 / 75 / 100 mg band |
Not required |
Not required |
Not required |
Not required |
| 3 |
SC |
Same as C1 |
Not required |
Not required |
100 / 150 / 200 mg/ml |
Not required |
Not required |
| 4 |
SC |
Same as C1 |
50-100 mg |
Not required |
Not required |
Not required |
Not required |
| 5 |
SC |
Same as C1 |
Not required |
weekly required |
Not required |
Not required |
Not required |
| 6 |
SC |
Same as C1 |
Not required |
weekly required (via C5 dependence) |
Not required |
±30% week-to-week avg constraint |
Not required |
| 7 |
SC |
Same as C1 |
Not required |
Not required |
Not required |
continuation required |
Not required |
| 8 |
SC |
Same as C1 and C7 |
Not required |
Not required |
Not required |
post-adjustment allowed same/different |
Not required |
| 9 |
SC |
Same as C1 |
Not required |
Not required |
Not required |
Not required |
800-1100 ng/dl |
| 10 |
SC |
Same as C1 |
Not required |
Not required |
Not required |
Not required |
500-800 ng/dl |
| 11 |
SC |
Same as C1 |
Not required |
Not required |
Not required |
Not required |
350-500 ng/dl |
Core legal scope: what is “the invention” at claim level?
From a patentability and enforcement lens, the scope centers on a specific clinical dosing workflow:
- SC route titration using multiple candidate SC doses.
- Selection of the lowest SC dose that achieves a desired testosterone plasma level.
- Equivalence anchored to an IM dose that produces the same desired plasma concentration.
- Possible operational constraints that tighten method embodiments:
- 50-100 mg “lowest dose” band
- SC formulation strengths at 100/150/200 mg/ml
- weekly dosing
- ±30% week-to-week average stability once the target is achieved
- continuation and potential post-target adjustments
- explicit target plasma bands (350-500, 500-800, 800-1100 ng/dl)
How could this claim be designed around? (competitive freedom to operate logic)
The claim design implies several clearance-sensitive pivot points. Changes that may fall outside the claim depending on evidence of infringement:
- Route benchmark removal: If the method does not use an IM dose equivalence concept (for example, uses only SC dose targets without reference to IM performance), it may avoid a key claim element in C1’s comparative framing.
- No “lowest SC dose” selection: If a regimen uses fixed SC dosing without selecting the lowest dose meeting target based on titration outcomes, it can diverge from the “select the lowest dose” requirement.
- Target range outside dependent claims: Using a target outside 350-500, 500-800, or 800-1100 would avoid those specific dependent claim embodiments, though C1 still covers “desired plasma concentration” generally unless the practitioner ties it to those specific bands.
- Avoid weekly schedule: If dosing is not weekly (e.g., biweekly or daily), dependent claim 5 and downstream claim 6 can be avoided.
- Avoid ±30% average-week constraint: A regimen that does not maintain the ±30% week-to-week average criterion after reaching target may avoid claim 6.
- Dose strength outside 50-100 mg or SC concentration outside 100/150/200 mg/ml: This can avoid claims 2-4 and claim 3 dependent scope, while still potentially falling within C1 if “lowest dose” in C1 is met and plasma target equivalence is addressed.
U.S. patent landscape: what can be concluded from the claim text provided
The prompt provides claim text for US 11,844,804 but does not provide the patent’s bibliographic metadata, assignee, specification details, citation set, priority data, family members, continuation status, prosecution history, or related patents. Without those data, a complete and accurate U.S. landscape map (including overlap with related testosterone SC delivery patents, titration algorithm patents, and product-specific composition patents) cannot be produced.
What can be stated precisely from the claims alone is the type of surrounding technological field the patent sits in:
- testosterone replacement therapy regimens,
- SC testosterone delivery and concentration-specific products (mg/ml),
- dosing interval protocols (weekly),
- pharmacokinetic-driven titration (plasma level targets),
- route comparison against IM baselines.
Those fields are crowded in practice, but the absence of the actual assignee and cited references prevents building a defensible “who owns what” landscape for enforcement or investment decisions.
Enforcement focus: which claim limitations are most likely to matter in practice?
For litigation or licensing, the highest-friction limitations are typically those that require evidence of:
- titration methodology in the presence of plasma measurements,
- the “lowest SC dose” selection process,
- the comparison anchoring to IM dosing that achieves the same desired plasma concentration.
The downstream limitations (mg ranges, mg/ml strengths, weekly schedule, ±30% week-to-week stability, and explicit ng/dl targets) can help narrow the method to specific real-world regimen playbooks, but they also create more opportunities for clinicians to operate outside those embodiments.
Key Takeaways
- US 11,844,804 is a method patent focused on SC testosterone titration with selection of the lowest SC dose that achieves a desired plasma level anchored to IM equivalence.
- Dependent claims narrow embodiments to 50-100 mg lowest doses, SC formulation strengths (100/150/200 mg/ml), weekly dosing, and ±30% week-to-week maintenance after target achievement.
- The patent also locks explicit target testosterone plasma ranges at 350-500, 500-800, and 800-1100 ng/dl for dependent claim coverage.
- Competitive design-around risk is concentrated in the “lowest SC dose” selection and the IM equivalence framing, with additional carve-outs via dose range, formulation strength, non-weekly schedules, and maintenance tolerance deviations.
FAQs
-
Is US 11,844,804 a drug product patent?
No. Its claims are method claims covering a clinical titration protocol rather than the testosterone molecule or formulation alone.
-
What is the core novelty in claim 1?
The method selects the lowest SC dose that achieves a desired plasma concentration that is equivalent to what an IM dose would produce.
-
Does the patent require weekly dosing?
Weekly dosing appears in dependent claim 5. Claim 1 does not require weekly dosing.
-
What maintenance criterion is recited?
Dependent claim 6 requires that after reaching the target, the average plasma concentration in a subsequent week is within ±30% of the prior week’s average.
-
Which plasma testosterone ranges are expressly claimed?
Dependent claims specify about 350-500, 500-800, and 800-1100 ng/dl.
References
- United States Patent No. 11,844,804. Claims 1-11 (provided in prompt).
